|
|
Article: Acarbose reduces MI risk in type 2 diabetes by nearly two-thirds in metaanalysis.(Metabolic Disorders)(Brief Article)
- Article from:
- Family Practice News
- Article date:
- December 1, 2005
- Author:
CopyrightCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VANCOUVER, B.C. -- Acarbose markedly reduces the risk of cardiovascular events in patients with type 2 diabetes, according to a metaanalysis of seven randomized trials, Dieter Petzinna, M.D., said at a meeting sponsored by the International Academy of Cardiology.
The trials, each double-blind, placebo-controlled, and of at least 1 year's duration, included 2,180 patients with type 2 diabetes mellitus. Roughly 60% of participants were on background intensive cardiovascular risk reduction therapy, including statins, ACE inhibitors, and antiplatelet agents.
The primary end point in the metaanalysis was the occurrence of any newly diagnosed cardiovascular ...